Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma

Autor: Khê Hoang-Xuan, Jean-Yves Delattre, László Sipos, Martin J.B. Taphoorn, Hans J.J.A. Bernsen, Denis Lacombe, Marc Frenay, Alba A. Brandes, Thierry Gorlia, Martin J. van den Bent, Charles J. Vecht, Roelien H. Enting, Johan M. Kros, Cees C. Tijssen, Pim J. French, Mathilde C.M. Kouwenhoven, Winand N.M. Dinjens, Anouk Allgeier, Wolfgang Grisold

Publikováno v: Journal of Clinical Oncology, 31(3), 344-350. American Society of Clinical Oncology
van den Bent, M J, Brandes, A A, Taphoorn, M J B, Kros, J M, Kouwenhoven, M C M, Delattre, J Y, Bernsen, H J J A, Frenay, M, Tijssen, C C, Grisold, W, Sipos, L, Enting, R H, French, P J, Dinjens, W N M, Vecht, C J, Allgeier, A, Lacombe, D, Gorlia, T & Hoang-Xuan, K 2013, ' Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951 ', Journal of Clinical Oncology, vol. 31, no. 3, pp. 344-350 . https://doi.org/10.1200/JCO.2012.43.2229
Journal of Clinical Oncology, 31(3), 344-350. AMER SOC CLINICAL ONCOLOGY

Purpose Anaplastic oligodendroglioma are chemotherapy-sensitive tumors. We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarbazine, lomustine, and vincristine (PCV) chemotherapy to ra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a6347dec5dc9d93f4efcc0269e67e01
https://doi.org/10.1200/JCO.2012.43.2229

New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951

Autor: Hans J.J.A. Bernsen, Martin J.B. Taphoorn, Denis Lacombe, Jean-Yves Delattre, Thierry Gorlia, Alba A. Brandes, Mathilde C.M. Kouwenhoven, Johan M. Kros, Cees C. Tijssen, Martin J. van den Bent, Marc Frenay

Publikováno v: Gorlia, T, Delattre, J Y, Brandes, A A, Kros, J M, Taphoorn, M J B, Kouwenhoven, M C M, Bernsen, H J J A, Frenay, M, Tijssen, C C, Lacombe, D & van den Bent, M J 2013, ' New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951 ', European Journal of Cancer, vol. 49, no. 16, pp. 3477-3485 . https://doi.org/10.1016/j.ejca.2013.06.039
European Journal of Cancer, 49(16), 3477-3485. Pergamon
European Journal of Cancer, 49(16), 3477-3485. Elsevier Ltd.

Background: The prognosis of patients with anaplastic oligodendrogliomas (AOD) and oligoastrocytomas (AOA) is variable. Biomarkers might be helpful to identify more homogeneous disease subtypes and improve therapeutic index. The aim of this study is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76c1fc8662cb927e1bd56f020c0193cc
https://research.vumc.nl/en/publications/1bb3f40d-7599-4110-8449-b1ba3c379126

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial

Autor: Johannes M. Kros, Mathilde C.M. Kouwenhoven, Thierry Gorlia, Charles J. Vecht, Denis Lacombe, Martin J. van den Bent, Marc Frenay, Hans J.J.A. Bernsen, Cees C. Tijssen, Laslo Sipos, H. Haaxma-Reiche, Alba A. Brandes, Marc Sanson, Anouk Allgeier, Martin J B Taphoorn, Wolfgang Grisold, Antoine F. Carpentier

Publikováno v: Journal of Clinical Oncology, 24(18), 2715-2722. American Society of Clinical Oncology
Journal of Clinical Oncology, 24(18), 2715-2722. AMER SOC CLINICAL ONCOLOGY

Purpose Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas. We investigated, in a multicenter randomized controlled trial, whether adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy improv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c29eb32884121c2b0b2a57a110116a8
https://pure.eur.nl/en/publications/27187c05-1dcc-4dc4-8aee-1117ecf793a2